We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.49B
AUM Growth
-$345M
Cap. Flow
-$1.43B
Cap. Flow %
-31.97%
Top 10 Hldgs %
44.77%
Holding
117
New
16
Increased
17
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$76.9M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$73.8M
3
AHCO icon
AdaptHealth
AHCO
+$54.6M
4
ACH
Accendra Health
ACH
+$48.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$47.9M

Top Sells

Rank Stock Value
1
PHR icon
Phreesia
PHR
+$44.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$42M
3
IMGN
Immunogen Inc
IMGN
+$31.5M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.6M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 62.79%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
51
Vaxcyte
PCVX
$7.95B
$11.1M 0.25%
295,000
-405,000
-58% -$17.2M
PRME icon
52
Prime Medicine
PRME
$544M
$10.9M 0.24%
885,314
– –
FUSN
53
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$10.6M 0.24%
+2,823,000
New +$11.1M
VERA icon
54
Vera Therapeutics
VERA
$2.4B
$10.1M 0.22%
+1,300,000
New +$10M
NUVB icon
55
Nuvation Bio
NUVB
$2.28B
$9.72M 0.22%
5,854,860
– –
GPCR icon
56
Structure Therapeutics
GPCR
$3.37B
$8.92M 0.2%
+375,000
New +$8.81M
OMIC
57
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$7.81M 0.17%
215,029
– –
PACB icon
58
Pacific Biosciences
PACB
$432M
$7.53M 0.17%
+650,000
New +$6.46M
BLUE
59
DELISTED
bluebird bio
BLUE
$6.92M 0.15%
+108,750
New +$12.4M
ALEC icon
60
Alector
ALEC
$168M
$6.53M 0.15%
1,055,192
– –
CSTL icon
61
Castle Biosciences
CSTL
$740M
$6.18M 0.14%
272,135
– –
FHTX icon
62
Foghorn Therapeutics
FHTX
$304M
$4.82M 0.11%
777,525
– –
CABA icon
63
Cabaletta Bio
CABA
$440M
$3.84M 0.09%
464,252
– –
NYXH
64
Nyxoah
NYXH
$144M
$3.4M 0.08%
455,262
– –
ABEO icon
65
Abeona Therapeutics
ABEO
$340M
$2.45M 0.05%
869,565
– –
TOI icon
66
The Oncology Institute
TOI
$493M
$2.28M 0.05%
3,360,052
– –
ANNX icon
67
Annexon
ANNX
$813M
$2.25M 0.05%
583,913
– –
AFIB
68
DELISTED
Acutus Medical Inc
AFIB
$2M 0.04%
2,651,667
– –
RAIN
69
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$1.99M 0.04%
227,393
-2,568,868
-92% -$23.7M
ORTX
70
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.7M 0.04%
316,169
-2
-0% -$11
ROIVW
71
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$1.46M 0.03%
1,000,000
– –
CMAXW
72
DELISTED
CareMax, Inc. Warrant
CMAXW
$324K 0.01%
672,000
– –
MDVL
73
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$240K 0.01%
16,733
– –
BFLY.WS
74
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$195K ﹤0.01%
733,333
– –
NAMSW icon
75
NewAmsterdam Pharma Warrant
NAMSW
$76.2M
$171K ﹤0.01%
92,787
– –
1 2
3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2023 Portfolio in Review

As of Q1 2023, Deerfield Management held 117 positions worth $4.49B, down 7.1% from $4.83B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deerfield Management withdrew a net $1.43B in Q1 2023, closing 11 positions and reducing 12 holdings. Its most notable exit was Phreesia, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intra-Cellular Therapies Inc. worth $39.7M.

  • Deerfield Management's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 734,000 shares worth $39.7M.
  • Deerfield Management added most to Viatris in Q1 2023, an estimated $76.9M increase.
  • Deerfield Management's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $42M.
  • Deerfield Management fully exited Phreesia in Q1 2023, selling an estimated $44.2M.
  • Deerfield Management's ten largest holdings make up 45% of its $4.49B portfolio in Q1 2023.
  • Deerfield Management opened 16 new positions and closed 11 in Q1 2023.
  • Deerfield Management's portfolio value fell 7.1% quarter-over-quarter to $4.49B.

Based on Deerfield Management's 13F filing for Q1 2023, filed 15 May 2023.